Clinchoicesp. z o.o.
Other research and experimental development on natural sciences and engineering
Overview
Clinchoice is a global full-service contract research organization (CRO) that specializes in clinical development, post-marketing support, and functional service support for pharmaceuticals, medical devices, and consumer health products. The company conducts clinical studies, including advanced therapies like Chimeric Antigen Receptor T-cell (CAR-T) therapy targeting solid tumors. Clinchoice provides comprehensive solutions from early clinical development through to post-approval lifecycle management across various therapeutic areas.
Financials
The financial statement for 2024 has not yet been filed with the Financial Document Repository (past deadline).
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2023.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2000-07-10. Active
23 1240 1053 1111 0010 5612 4898
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jan 20, 2012 | Commercial Companies Code notice | |
| Nov 7, 2011 | Merger plan |
Public aid
4 public aid cases recorded, with a total value of $386,783.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $9,974 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $10,183 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $10,011 | Prezes Zakładu Ubezpieczeń Społecznych |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
Each member of the management board independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Clinchoice S.r.l. | 1,000 | $13,506.21 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Xin Ke (66)  | Natural person holding a senior management position in a parent entity (e.g. parent company). |
Competitors
Selected automatically: mainly by similarity of the business description, plus comparable revenue, industry (PKD code) and location. Only companies with a complete profile (including a logo and financial data) are shown. The list is indicative.
| Name | Revenue | Website | |
|---|---|---|---|
| Scope FluidicsS.A. | $3,082,936.61 | scopefluidics.com | |
| Read-GeneS.A. | $2,163,474.84 | read-gene.com | |
| Medsource Polskasp. z o.o. | $1,620,329.12 | medsource.com.pl | |
| Aslab ScienceP.S.A. | $1,504,132.17 | aslabsci.com | |
| FamicordtxS.A. | $1,365,068.41 | famicordtx.com | |
| Aurevia Polandsp. z o.o. | $1,330,077.42 | aurevia.com | |
| BiokineticaS.A. | $1,292,838.89 | biokinetica.com | |
| Saventic Healthsp. z o.o. | $1,089,246.05 | saventic.com | |
| COS LabP.S.A. | $1,028,123.83 | coslab.pl | |
| Ecoverseasp. z o.o. | $891,022.45 | coslab.pl |
Change history
| Date | Event |
|---|---|
| 2025-04-15 | Name change (Cromsource → Clinchoice) |
| 2012-11-16 | Address change (Lektykarska 25/20, 01-687, Warszawa → Gen. Józefa Zajączka 32, 01-510, Warszawa) |
| 2012-03-26 | Name change (Crom Polska → Cromsource) |
| 2007-05-08 | Share capital change (45,000.00 PLN → 50,000.00 PLN) |
| 2002-01-24 | Address change (Kasprowicza 151/201, 01-949, Warszawa → Lektykarska 25/20, 01-687, Warszawa) |
FAQ
Last updated: 2026-05-04